Read Time:8 Second
RAPT Therapeutics shares dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation drug.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
